Mankind Pharma has achieved an MSCI ESG rating of 'B', as announced on November 4, 2025. This rating, assigned by MSCI ESG Ratings and Research Private Limited, reflects the company's commitment to environmental, social, and governance factors. Notably, the ESG report was issued independently, indicating that Mankind Pharma did not engage MSCI for this evaluation. This significant development showcases the company's ongoing efforts to enhance its sustainability practices and corporate governance.

The announcement was formally communicated to both the BSE and NSE in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors and stakeholders can access the full disclosure on the company’s website at www.mankindpharma.com. The scrip code for Mankind Pharma on BSE is 543904, while its symbol on NSE is MANKIND. This rating could potentially influence investor perceptions and enhance Mankind Pharma's attractiveness to socially responsible investors looking for companies with robust ESG credentials.